FCFreya Cools

Freya Cools

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Freya Cools has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Paul Cos

    Laboratory for Microbiology, Parasitology and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium

    7 shared publications
  • Eveline Torfs

    Research and Development Department Flen Health Kontich Belgium

    6 shared publications
  • Guy Caljon

    Laboratory of Microbiology, Parasitology and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Universiteitsplein 1, B-2610, Wilrijk, Belgium

    4 shared publications
  • Louis Maes

    Laboratory of Microbiology, Parasitology and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Universiteitsplein 1, B-2610, Wilrijk, Belgium

    4 shared publications
  • Peter Delputte

    Laboratory for Microbiology, Parasitology and Hygiene, University of Antwerp, Wilrijk, Belgium

    4 shared publications
  • Bieke Vanhoutte

    Laboratory of Microbiology, Parasitology and Hygiene, Department of Pharmaceutical Sciences, University of Antwerp, Wilrijk, Belgium

    3 shared publications

Latest Publications

  • The synthesis and in vitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis

    by Davie Cappoen, Eveline Torfs, Tamara Meiresonne, Pieter Claes, Elena Semina, Francis Holvoet, Maíra Bidart de Macedo, Freya Cools, Tatiana Piller, An Matheeussen, et al.


  • Open Access

    Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae

    by Freya Cools, Eveline Torfs, Juliana Aizawa, Bieke Vanhoutte, Louis Maes, Guy Caljon, Peter Delputte, Davie Cappoen, Paul Cos

    Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Infection is linked to high morbidity and mortality rates and antibiotic resistance within this pathogen is on the rise. Therefore, there is a need for novel antimicrobial therapies. To lower the time and costs of the drug discovery process, alternative in vivo models should be considered. As such, Galleria mellonella larvae can be of great value. The larval immunity consisting of several types of haemocytes is remarkably similar to the human innate immune system. Furthermore, these larvae don’t require specific housing, are cheap and are easy to handle. In this study, the use of a G. mellonella infection model to study early pneumococcal infections and treatment is proposed. Firstly, the fitness of this model to study pneumococcal virulence factors is confirmed using streptococcal strains TIGR4, ATCC® 49619, D39 and its capsule-deficient counterpart R6 at different inoculum sizes. The streptococcal polysaccharide capsule is considered the most important virulence factor without which streptococci are unable to sustain an in vivo infection. Kaplan-Meier survival curves showed indeed a higher larval survival after infection with streptococcal strain R6 compared to strain D39. Then, the infection was characterized by determining the number of haemocytes, production of oxygen free radicals and bacterial burden at several time points during the course of infection. Lastly, treatment of infected larvae with the standard antibiotics amoxicillin and moxifloxacin was evaluated. Treatment has proven to have a positive outcome on the course of infection, depending on the administered dosage. These data imply that G. mellonella larvae can be used to evaluate antimicrobial therapies against S. pneumoniae, apart from using the larval model to study streptococcal properties. The in-depth knowledge acquired regarding this model, makes it more suitable for use in future research.


  • Streptococcus pneumoniae galU gene mutation has a direct effect on biofilm growth, adherence and phagocytosis in vitro and pathogenicity in vivo

    by F Cools, E Torfs, B Vanhoutte, M Bidart de Macedo, L Bonofiglio, M Mollerach, L Maes, G Caljon, P Delputte, D Cappoen, et al.

    Streptococcus pneumoniae, the most common cause of bacterial pneumonia, has developed a wide range of virulence factors to evade the immune system of which the polysaccharide capsule is the most important one. Formation of this capsule is dependent on the cps gene locus, but also involves other genes-like galU. The pyrophosphorylase encoded by galU plays a role in the UDP-glucose metabolism of prokaryotes and is required for the biosynthesis of capsular polysaccharides. In this paper, the effect of a galU mutation leading to a dysfunctional UDP-glucose pyrophosphorylase (UDPG:PP) on in vitro biofilm biomass, adherence to lung epithelial cells and macrophage phagocytosis is studied. Last, in vivo virulence using a Galleria mellonella model has been studied. We show that the mutation improves streptococcal adherence to epithelial cells and macrophage phagocytosis in vitro, while there is no definitive correlation on biofilm formation between parent and mutant strains. Moreover, in vivo virulence is attenuated for all mutated strains. Together, these results demonstrate that a galU mutation in S. pneumoniae influences host cell interactions in vitro and in vivo and can strongly influence the outcome of a streptococcal infection. As such, UDPG:PP is worth investigating further as a potential drug target.


  • Design, synthesis and antitubercular potency of 4-hydroxyquinolin-2(1H)-ones

    by Maíra Bidart de Macedo, Roman Kimmel, Damijana Urankar, Martin Gazvoda, Antonio Peixoto, Freya Cools, Eveline Torfs, Luc Verschaeve, Emerson Silva Lima, Antonín Lyčka, et al.


  • Synthesis and in vitro investigation of halogenated 1,3‐bis(4‐nitrophenyl)triazenide salts as antitubercular compounds

    by Eveline Torfs, Jure Vajs, Maíra Bidart de Macedo, Freya Cools, Bieke Vanhoutte, Yury Gorbanev, Annemie Bogaerts, Luc Verschaeve, Guy Caljon, Louis Maes, et al.

    The diverse pharmacological properties of the diaryltriazenes have sparked the interest to investigate their potential to be repurposed as antitubercular drug candidates. In an attempt to improve the antitubercular activity of a previously constructed diaryltriazene library, eight new halogenated nitroaromatic triazenides were synthesized and underwent biological evaluation. The potency of the series was confirmed against the Mycobacterium tuberculosis lab strain H37Ra, and for the most potent derivative, we observed a minimal inhibitory concentration of 0.85 μm. The potency of the triazenide derivatives against M. tuberculosis H37Ra was found to be highly dependent on the nature of the halogenated phenyl substituent and less dependent on cationic species used for the preparation of the salts. Although the inhibitory concentration against J774A.1 macrophages was observed at 3.08 μm, the cellular toxicity was not mediated by the generation of nitroxide intermediate as confirmed by electron paramagnetic resonance spectroscopy, whereas no in vitro mutagenicity could be observed for the new halogenated nitroaromatic triazenides when a trifluoromethyl substituent was present on both the aryl moieties.


  • Optimization and characterization of a murine lung infection model for the evaluation of novel therapeutics against Burkholderia cenocepacia

    by Bieke Vanhoutte, Davie Cappoen, Bidart de Macedo Maira, Freya Cools, Eveline Torfs, Tom Coenye, Wim Martinet, Guy Caljon, Louis Maes, Peter Delputte, et al.


  • Open Access

    The Role of Reactive Oxygen Species in Antibiotic-Induced Cell Death in Burkholderia cepacia Complex Bacteria

    by Heleen Van Acker, Jan Gielis, Marloes Acke, Freya Cools, Paul Cos, Tom Coenye

    It was recently proposed that bactericidal antibiotics, besides through specific drug-target interactions, kill bacteria by a common mechanism involving the production of reactive oxygen species (ROS). However, this mechanism involving the production of hydroxyl radicals has become the subject of a lot of debate. Since the contribution of ROS to antibiotic mediated killing most likely depends on the conditions, differences in experimental procedures are expected to be at the basis of the conflicting results. In the present study different methods (ROS specific stainings, gene-expression analyses, electron paramagnetic resonance, genetic and phenotypic experiments, detection of protein carbonylation and DNA oxidation) to measure the production of ROS upon antibiotic treatment in Burkholderia cepacia complex (Bcc) bacteria were compared. Different classes of antibiotics (tobramycin, ciprofloxacin, meropenem) were included, and both planktonic and biofilm cultures were studied. Our results indicate that some of the methods investigated were not sensitive enough to measure antibiotic induced production of ROS, including the spectrophotometric detection of protein carbonylation. Secondly, other methods were found to be useful only in specific conditions. For example, an increase in the expression of OxyR was measured in Burkholderia cenocepacia K56-2 after treatment with ciprofloxacin or meropenem (both in biofilms and planktonic cultures) but not after treatment with tobramycin. In addition results vary with the experimental conditions and the species tested. Nevertheless our data strongly suggest that ROS contribute to antibiotic mediated killing in Bcc species and that enhancing ROS production or interfering with the protection against ROS may form a novel strategy to improve antibiotic treatment.


  • Five Species of Coccidia (Apicomplexa: Eimeriidae), Including Four New Species, Identified in the Feces of Blue Wildebeest (Connochaetes taurinus) in Mikumi National Park, Tanzania

    by John James Debenham, Freya Cools, Fred Midtgaard, Lucy Jane Robertson

    During October 2013, 112 fecal samples were collected from wild blue wildebeest (Connochaetes taurinus) in Mikumi National Park, Tanzania, and examined for coccidians. Coccidia were present in 46% of samples, with wildebeest shedding 60 to 18 000 oocysts per gram feces (median, 300; mean, 1,236). Five species, including 4 new species, were identified. Oocysts of Eimeria gorgonis from 18% of samples were ellipsoidal, 23 × 18.4 µm, with a length/width (L/W) ratio of 1.3, oocyst wall 1-1.5 µm thick. Micropyle, oocyst residuum and polar granule absent. Oocysts of Eimeria donaldi n. sp. from 34% of samples were spherical to oblong, 13.4 × 12.3 µm, L/W ratio 1.1, oocyst wall 1 µm thick. Micropyle, oocyst residuum and polar granule absent. Oocysts of Eimeria nyumbu n. sp. were ellipsoidal, 30.8 × 22.1 µm, L/W 1.4, oocyst wall 2 µm thick. Large micropyle present, oocyst residuum and polar granule absent. Oocysts of Eimeria burchelli n. sp. in 16% of samples were 34.8 × 24.4 µm, L/W 1.4, oocyst wall 2-2.5 µm thick, with a brown, lightly stippled outer layer. Micropyle present, oocyst residuum and polar granule absent. Oocysts of Eimeria sokoine n. sp. in 5% of samples were 45.8 × 29 µm, L/W 1.6, oocyst wall 3-4 µm thick with a dark brown, very rough, stippled outer layer. Micropyle present, oocyst residuum and polar granule absent. There was no apparent cross transmission of coccidia found in blue wildebeest with those generally reported to infect domestic cattle.